Knowledge Library

Inflammatory Bowel Disease Models

We offer an extensive panel of inflammatory bowel disease models in mice and rats, including genetically modified, chemically induced, and adoptive transfer-related IBD models. Let our experts help you choose the best IBD animal models to advance your research programs. Learn more about our platform of inflammation models  

Resource Type: Latest Science Presentation
Resource Topic: Autoimmune and Inflammatory Diseases Hit-to-Lead in vivo Pharmacology Lead Optimization

VIEW

DNA-Encoded Macrocyclic Peptide Libraries Enable the Discovery of a Neutral MDM2–p53 Inhibitor

Macrocyclic peptides are an emerging molecular class for targeting intracellular protein–protein interactions (PPIs) and for providing an oral modality for drug targets. Herein, we use DNA-encoded cyclic peptide libraries to discover a neutral nonapeptide, UNP-6457, that inhibits MDM2–p53 interaction with an IC50 of 8.9 nM. These studies showcase how tailored DEL libraries can directly yield …Read More >

Resource Type: Latest Science Publication
Resource Topic: Biochemical Assays DNA-Encoded Library (DEL) Hit Finding Hit-to-Lead Lead Optimization Oncology Structural Biology

VIEW

Orthotopic and Metastasis Syngeneic Models

Our comprehensive panel of orthotopic and metastasis syngeneic models includes: 17 orthotopic/disseminated models covering 10 cancer types; Organ-based orthotopic models of solid tumor cell lines; IV injection disseminated models of hematopoietic cancer cell lines; 13 experimental metastasis models covering 7 cancer types

Resource Type: Latest Science Presentation
Resource Topic: Lead Optimization Oncology Tumor Models

VIEW

DLL3-Related PDX Models

DLL3 related lung cancer PDX models, validated by RNA-Seq and IHC staining

Resource Type: Latest Science Presentation
Resource Topic: Lead Optimization Oncology Tumor Models

VIEW

c-MET Related In Vivo Models

c-Met is a receptor tyrosine kinase, a/k/a hepatocyte growth factor receptor (HGFR). As a type of proto-oncogene, c-Met overexpression, amplification or gene mutation can promote the development of multiple cancer types, including gastric, liver, lung, breast, pancreatic cancer, and glioblastoma (through the stimulation of multiple signaling pathways).  As a result, c-Met is considered a clinically …Read More >

Resource Type: Latest Science Presentation
Resource Topic: Lead Optimization Oncology Tumor Models

VIEW

Discovery of Potent and Selective Dual Leucine Zipper Kinase/Leucine Zipper-Bearing Kinase Inhibitors

Dual leucine zipper kinase (DLK) and leucine zipper-bearing kinase (LZK) have emerged as key regulators of neuronal degeneration and axon growth.  WuXi AppTec scientists recently contributed to a research article in the Journal of Medicinal Chemistry demonstrating the use of ligand- and structure-based drug design approaches to discover an amino-pyrazine chemical series of DLK and …Read More >

Resource Type: Latest Science Publication
Resource Topic: Biochemical Assays Biomarkers Central Nervous System & Pain Discovery Chemistry Lead Optimization Small Molecules

VIEW

AACR 2023: Integrated platform enables KRAS-targeted drugs discovery

Discover our end-to-end KRAS services platform presented at AACR 2023! WuXi AppTec scientists have established a comprehensive panel of assays on key mutants of KRAS, including G12C and G12D, to empower KRAS-targeted drug discovery. Our suite of services includes 2D/3D cell proliferation assays (utilizing cell lines harboring single or double KRAS mutations) as well as …Read More >

Resource Type: Poster
Resource Topic: Biochemical Assays Biophysical Assays Cell-based Assays Hit Finding Hit-to-Lead Lead Optimization Oncology Small Molecules Structural Biology Tumor Models

VIEW

AACR 2023: Therapeutic potential of polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma

In our latest AACR poster, WuXi AppTec scientists characterize the therapeutic potential of the antibody-drug conjugate (ADC) polatuzumab vedotin across a panel of established, in-house diffuse large B-cell lymphoma (DLBCL) patient-derived xenograft (PDX) models. Among our panel of lymphoma PDX models, three represent the germinal center B-cell (GCB) subtype. The authors show that 50% of …Read More >

Resource Type: Poster
Resource Topic: Antibody Drug Conjugate Lead Optimization Oncology Tumor Models

VIEW

AACR 2023: A tailored platform enables BRAF-targeted drug discovery and precision medicine

In our latest AACR poster, WuXi AppTec scientists showcase the development of a tailored platform of patient-derived xenograft (PDX) models based on the classification of BRAF mutations. This panel covers all 3 classes of BRAF mutants, including subtypes for which viable therapeutic options remain limited. The authors demonstrate that these PDX models are responsive to …Read More >

Resource Type: Poster
Resource Topic: Lead Optimization Oncology Small Molecules Tumor Models

VIEW


Resource Topics